Physician profile
Ping S Chu
NPI 1316957368
$6,181.76
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,520 · 2020: $1,714 · 2021: $1,272 · 2022: $41.77 · 2023: $110 · 2024: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $525 · Food and Beverage: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $525.00 |
| Food and Beverage | $109.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $866.81 | 2019-2021 | |
| Daiichi Sankyo INC. | $646.03 | 2019-2024 | Enhertu |
| Eisai INC. | $503.97 | 2019-2021 | |
| Pfizer INC. | $416.44 | 2019-2021 | |
| Amgen INC. | $401.36 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $302.96 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $297.02 | 2019-2021 | |
| Glaxosmithkline, LLC. | $219.37 | 2020-2023 | Jemperli, Zejula |
| Abbvie INC. | $205.31 | 2020-2021 | |
| Celgene Corporation | $189.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $173.09 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.45 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $163.81 | 2019-2022 | |
| Astellas Pharma US INC | $136.93 | 2019-2021 | |
| Emd Serono, INC. | $130.29 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $128.49 | 2020-2023 | Pemazyre, Monjuvi |
| Exelixis INC. | $119.56 | 2019-2020 | |
| Lilly USA, LLC | $118.27 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $114.79 | 2019-2021 | |
| Janssen Biotech, INC. | $109.54 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $91.18 | 2019-2021 | |
| Secura Bio, INC. | $77.59 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $68.19 | 2019-2020 | |
| Macrogenics, INC. | $65.17 | 2022-2023 | |
| Kyowa Kirin, INC. | $59.28 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $55.16 | 2019-2021 | |
| Genentech USA, INC. | $43.90 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $42.34 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.66 | 2019 | |
| Myovant Sciences INC. | $38.01 | 2021 | |
| Dendreon Pharmaceuticals LLC | $36.22 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $35.47 | 2019 | |
| Sirtex Medical INC | $24.89 | 2019 | |
| Morphosys, US INC. | $24.22 | 2023 | Monjuvi |
| Taiho Oncology, INC. | $17.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.00 | 2019 | |
| Dova Pharmaceuticals | $15.34 | 2020 | |
| Genzyme Corporation | $15.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ping Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.